Judy E. Garber
#97,275
Most Influential Person Now
Medical researcher
Judy E. Garber's AcademicInfluence.com Rankings
Judy E. Garbermedical Degrees
Medical
#1220
World Rank
#1539
Historical Rank
Oncology
#62
World Rank
#66
Historical Rank
Public Health
#208
World Rank
#217
Historical Rank
Judy E. Garberphilosophy Degrees
Philosophy
#4777
World Rank
#7418
Historical Rank
Logic
#2166
World Rank
#3096
Historical Rank
Download Badge
Medical Philosophy
Why Is Judy E. Garber Influential?
(Suggest an Edit or Addition)According to Wikipedia, Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.
Judy E. Garber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer (1993) (2439)
- Mutational Processes Molding the Genomes of 21 Breast Cancers (2012) (1622)
- Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. (2002) (1469)
- Molecular definition of breast tumor heterogeneity. (2007) (1415)
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial (2010) (1217)
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. (2010) (1008)
- Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. (1999) (979)
- Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 (1997) (939)
- Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. (2010) (912)
- Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2004) (865)
- The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome (2006) (845)
- Exemestane for breast-cancer prevention in postmenopausal women. (2011) (810)
- Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. (1999) (676)
- Genetic/familial high-risk assessment: breast and ovarian. (2010) (648)
- A candidate precursor to serous carcinoma that originates in the distal fallopian tube (2007) (629)
- Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer (1997) (613)
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) (604)
- NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. (2009) (575)
- Hereditary cancer predisposition syndromes. (2005) (555)
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. (2017) (554)
- Multiple primary cancers in families with Li-Fraumeni syndrome. (1998) (542)
- The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. (1993) (537)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. (2015) (534)
- Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. (2008) (527)
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. (2007) (491)
- BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. (2002) (488)
- Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. (1998) (468)
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (2016) (462)
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
- Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. (1996) (445)
- Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. (1997) (442)
- Triple-Negative Breast Cancer: Risk Factors to Potential Targets (2008) (430)
- Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2005) (412)
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
- Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. (2012) (403)
- Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. (1996) (400)
- Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer (1994) (398)
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
- A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) (396)
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel (2015) (391)
- Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
- Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. (1992) (373)
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. (2016) (370)
- Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (2002) (369)
- Genetic/familial high-risk assessment: breast and ovarian. (2010) (366)
- BRCA2 germline mutations in male breast cancer cases and breast cancer families (1996) (363)
- Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. (2001) (358)
- A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
- Germ-line msh6 mutations in colorectal cancer families. (1999) (349)
- Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine (2014) (339)
- Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. (2006) (328)
- Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. (2018) (326)
- Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. (2006) (322)
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. (2015) (320)
- Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. (1995) (318)
- Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. (1998) (316)
- Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families (1996) (313)
- Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. (2016) (306)
- Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 (2008) (304)
- Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. (1993) (303)
- Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (2017) (302)
- An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. (1995) (299)
- Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (2013) (283)
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. (2020) (281)
- RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. (2007) (276)
- Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine (2013) (275)
- Follow-up study of twenty-four families with Li-Fraumeni syndrome. (1991) (272)
- Docetaxel administered on a weekly basis for metastatic breast cancer. (2000) (267)
- Counselling framework for moderate-penetrance cancer-susceptibility mutations (2016) (264)
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. (2008) (262)
- Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. (1999) (259)
- Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. (2000) (257)
- A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. (2002) (247)
- Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
- PARP inhibitors in the management of breast cancer: current data and future prospects (2015) (238)
- Complementary and alternative medicine use among women with breast cancer. (2002) (228)
- Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 (1999) (227)
- Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations inMSH2 and MLH1 (2000) (223)
- Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. (2015) (222)
- Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. (2000) (220)
- Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (2004) (218)
- Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study (2001) (216)
- Breast Cancer Screening and Diagnosis Clinical Practice Guidelines in Oncology. (2006) (213)
- A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26–35) (2007) (213)
- Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. (2014) (209)
- Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? (2013) (209)
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
- Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk (2011) (206)
- Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing (2018) (204)
- The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer (2017) (203)
- Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. (2002) (200)
- Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. (2019) (196)
- Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. (1995) (196)
- Benefits of Colonoscopic Surveillance and Prophylactic Colectomy in Patients with Hereditary Nonpolyposis Colorectal Cancer Mutations (1998) (192)
- Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease (2011) (187)
- Germline E-cadherin mutations in familial lobular breast cancer (2007) (184)
- Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer (2009) (183)
- Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. (2009) (181)
- Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. (2001) (180)
- Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. (1999) (178)
- Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. (2000) (178)
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy (2010) (169)
- Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. (2016) (168)
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. (2020) (167)
- Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. (2006) (167)
- Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort (2012) (162)
- Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. (2014) (158)
- Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. (2005) (156)
- Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (154)
- Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. (2000) (152)
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. (2014) (149)
- Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study (2018) (149)
- Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. (1999) (145)
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. (2017) (145)
- Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. (1998) (145)
- Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis (2017) (139)
- Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. (2001) (137)
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (2016) (136)
- VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy (2008) (134)
- Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing (2016) (134)
- BRCA1 haploinsufficiency for replication stress suppression in primary cells (2014) (132)
- BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2 (2018) (131)
- Germline TP53 Mutations and the Changing Landscape of Li–Fraumeni Syndrome (2014) (131)
- Transforming Cancer Prevention through Precision Medicine and Immune-oncology (2016) (128)
- Hereditary diffuse gastric cancer: association with lobular breast cancer (2007) (127)
- Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study (2013) (124)
- Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
- Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. (1992) (121)
- Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk (2013) (120)
- Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies (2015) (120)
- Evolutionary pathways in BRCA1-associated breast tumors. (2012) (120)
- Gastric cancer in individuals with Li-Fraumeni syndrome (2011) (117)
- Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. (2006) (115)
- PALB2 mutations in familial breast and pancreatic cancer (2011) (115)
- Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. (1996) (115)
- The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions (2012) (114)
- DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
- BRCA1/2 testing: therapeutic implications for breast cancer management (2018) (110)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
- Cancer variation associated with the position of the mutation in the BRCA2 gene (2004) (108)
- Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. (2002) (105)
- The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (103)
- Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (103)
- American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. (2009) (103)
- Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? (2007) (103)
- Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. (2002) (102)
- Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study (2016) (101)
- Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. (1995) (99)
- Precancer Atlas to Drive Precision Prevention Trials. (2017) (98)
- Hepatoblastoma and familial adenomatous polyposis. (1988) (97)
- Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. (2000) (96)
- Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. (2016) (95)
- Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (95)
- Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers (2005) (93)
- Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. (2013) (92)
- Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. (2017) (92)
- Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers (2010) (90)
- Disclosure of familial genetic information: perceptions of the duty to inform. (2000) (90)
- Using machine learning to parse breast pathology reports (2016) (90)
- Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features (2010) (88)
- Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer (2020) (88)
- Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. (2012) (87)
- Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms (1991) (87)
- The feasibility of using natural language processing to extract clinical information from breast pathology reports (2012) (86)
- Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages (2020) (86)
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. (2009) (86)
- An Alu‐mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10 (2000) (85)
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (84)
- Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. (2007) (83)
- Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D (2020) (80)
- Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. (2013) (80)
- Uptake of BRCA1/2 Genetic Testing in a Randomized Trial of Telephone Counseling (2014) (80)
- Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers (2011) (79)
- Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
- Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? (1998) (78)
- Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. (1998) (77)
- Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers (2004) (76)
- BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
- Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. (2008) (75)
- Breast cancer screening and diagnosis. (2006) (75)
- Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers (2009) (74)
- Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. (2019) (74)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
- Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts (2007) (73)
- Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer (1998) (73)
- TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). (2020) (72)
- Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. (2014) (72)
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
- BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. (2016) (69)
- Shared heritability and functional enrichment across six solid cancers (2018) (67)
- Breast cancer risk reduction. (2010) (66)
- Research issues affecting preoperative systemic therapy for operable breast cancer. (2008) (66)
- Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers (2019) (65)
- Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing (2018) (64)
- Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. (2015) (63)
- Progress in the management of gynecologic cancer: consensus summary statement. (2003) (63)
- Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers (2010) (63)
- Prevalence of BRCA1 mutations in triple negative breast cancer (BC). (2006) (62)
- Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care (2016) (62)
- Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes (2020) (62)
- The impact of a brief coping skills intervention on adherence to breast self‐examination among first‐degree relatives of newly diagnosed breast cancer patients (1999) (60)
- Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
- BRCA1/2 genetic testing in the community setting. (2002) (60)
- The impact of a brief Problem-Solving Training intervention for relatives of recently diagnosed breast cancer patients (1998) (59)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
- Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers (2014) (58)
- NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Risk Reduction (2010) (57)
- Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. (2011) (57)
- Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. (2006) (57)
- Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. (2007) (56)
- Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial (2010) (56)
- American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. (2009) (56)
- Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. (2006) (55)
- Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. (2001) (55)
- A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer (2015) (55)
- Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1 (2000) (54)
- Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. (2010) (54)
- Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients (2017) (54)
- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers (2006) (54)
- RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. (2008) (54)
- F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. (2008) (54)
- Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers (2009) (53)
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (53)
- Leveraging premalignant biology for immune-based cancer prevention (2016) (52)
- Accuracy of cancer family histories: comparison of two breast cancer syndromes. (2004) (51)
- Precision Prevention and Early Detection of Cancer: Fundamental Principles. (2018) (51)
- Guidelines for Genetic Risk Assessment of Hereditary Breast and Ovarian Cancer: Early Disagreements and Low Utilization (2009) (51)
- A population-based study of Ashkenazi Jewish women’s attitudes toward genetic discrimination and BRCA1/2 testing (2002) (49)
- Acceptance of invitations for p53 and BRCA1 predisposition testing: Factors influencing potential utilization of cancer genetic testing (1996) (49)
- Estrogen receptor signaling is reprogrammed during breast tumorigenesis (2019) (49)
- Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary cancer and how much do they worry? (2013) (49)
- Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. (2018) (48)
- Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. (2006) (47)
- Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. (2009) (47)
- Oral Contraceptives and the Risk of Breast Cancer in BRCA 1 and BRCA 2 Mutation Carriers (2002) (47)
- Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. (2011) (46)
- Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? (2015) (46)
- Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. (2009) (46)
- The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. (2006) (46)
- Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. (2012) (45)
- Targeting the missing links for cancer therapy (2011) (45)
- A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
- Time to check CHEK2 in families with breast cancer? (2008) (44)
- Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy (2008) (44)
- Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers (2010) (44)
- Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. (1991) (43)
- Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study (2017) (42)
- Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling (2016) (42)
- Prevalence of germline TP53 mutations in HER2+ breast cancer patients (2013) (41)
- Choroid plexus tumors in the breast cancer–sarcoma syndrome (1990) (41)
- Comprehensive management of disseminated breast cancer (1990) (41)
- Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. (2005) (41)
- Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma (2019) (40)
- Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis (2019) (40)
- Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor (2000) (40)
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale (2016) (39)
- Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. (2009) (39)
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (39)
- TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). (2020) (38)
- The Li–Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube (2010) (38)
- Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology (2015) (38)
- Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy (2018) (38)
- Parent decision‐making around the genetic testing of children for germline TP53 mutations (2015) (38)
- Physicians' experiences with BRCA1/2 testing in community settings. (2008) (38)
- AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study (2007) (37)
- Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers (2015) (37)
- Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis (2010) (36)
- Carcinoembryonic antigen in breast nipple aspirate fluid. (1998) (36)
- RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. (2015) (36)
- p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome (1999) (35)
- Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). (2009) (35)
- Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. (2000) (35)
- Intentions for risk‐reducing surgery among high‐risk women referred for BRCA1/BRCA2 genetic counseling (2015) (35)
- The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. (2006) (35)
- Complementary medicine use among women enrolled in a genetic testing program. (2003) (34)
- Statin Use and Breast Cancer Risk in the Nurses' Health Study (2016) (34)
- Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. (2012) (34)
- Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers (2018) (34)
- Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? (2011) (32)
- DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer (2010) (32)
- Li-Fraumeni Syndrome (2001) (32)
- TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. (2011) (32)
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
- Ductal Lavage of Fluid-Yielding and Non–Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk (2005) (31)
- Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ (2019) (31)
- Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children. (2012) (31)
- Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes (2004) (31)
- Decisional Outcomes of Maternal Disclosure of BRCA1/2 Genetic Test Results to Children (2013) (31)
- Behavioral risk factors among women presenting for genetic testing. (2000) (31)
- Breast Cancer Prevention: Patient Decision Making and Risk Communication in the High Risk Setting (2010) (30)
- Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry. (1997) (30)
- The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. (2006) (30)
- Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. (2009) (30)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
- Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer (2016) (28)
- OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). (2015) (28)
- Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch Syndrome (2011) (28)
- Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set (2021) (28)
- Genetic susceptibility for breast cancer--risk assessment and counseling. (2001) (28)
- Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. (2006) (27)
- Talking to Children About Maternal BRCA1/2 Genetic Test Results: A Qualitative Study of Parental Perceptions and Advice (2013) (27)
- Screening with whole‐body magnetic resonance imaging in pediatric subjects with Li–Fraumeni syndrome: A single institution pilot study (2018) (27)
- Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk (2020) (26)
- Prostate-specific antigen in nipple aspirate (1996) (26)
- Prophylactic oophorectomy and hormone replacement therapy: protection at what price? (2004) (26)
- The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study (2016) (26)
- Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. (2011) (26)
- Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. (2012) (25)
- A counseling framework for moderate-penetrance colorectal cancer susceptibility genes (2018) (25)
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
- Cancer surveillance is often inadequate in people at high risk for colorectal cancer (2003) (25)
- Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions (2018) (24)
- Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS) (2015) (23)
- Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS) (2018) (23)
- Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170 (2016) (22)
- Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers (2014) (22)
- BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry (2019) (22)
- A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
- OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. (2021) (22)
- Cancer prevention and the American Society of Clinical Oncology. (2004) (21)
- Complementary Medicine Use before and 1 Year Following Genetic Testing for BRCA1/2 Mutations (2006) (21)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (20)
- Genetic testing in young women with breast cancer: results from a Web-based survey. (2010) (20)
- Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? (2011) (20)
- Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
- Managing hereditary breast cancer risk in women with and without ovarian cancer. (2017) (19)
- Homologous Recombination De fi ciency ( HRD ) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) (19)
- Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers (2011) (19)
- Adjuvant systemic therapy for patients with node‐negative tumors (1990) (19)
- Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer (2003) (18)
- Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. (2009) (18)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers (2011) (18)
- Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing. (2019) (18)
- Defining etiologic heterogeneity in breast cancer using genetic biomarkers. (1997) (18)
- Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
- The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women (2016) (17)
- Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (17)
- Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. (2003) (17)
- A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings (2018) (17)
- A 40-year-old woman with a strong family history of breast cancer. (1999) (17)
- Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis (2019) (17)
- Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2 (2014) (17)
- Testing for inherited cancer susceptibility. (1996) (17)
- P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. (2011) (17)
- Inherited TP53 Variants and Risk of Prostate Cancer. (2021) (17)
- Family history and breast cancer. Probabilities and possibilities. (1993) (17)
- Ethical Issues in Cancer Genetics: 1) Whose Information Is It? (2006) (17)
- MATERNAL HEALTH Illiteracy and maternal health: educate or die (1993) (17)
- Ethical, social and counselling issues in hereditary cancer susceptibility. (1995) (17)
- PARP inhibition in breast cancer: progress made and future hopes (2022) (17)
- The use of chemotherapy in metastatic breast cancer. (1989) (16)
- Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers (2011) (16)
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. (2022) (16)
- Transcriptome-wide association study of breast cancer risk by estrogen-receptor status (2020) (16)
- Breast Cancer Risk Reduction, Version 2.2015. (2015) (16)
- Melanoma and soft tissue sarcoma in seven patients (1990) (16)
- Testing for cancer genes: Decisions, decisions (1995) (16)
- Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin (2009) (15)
- A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
- Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up (2017) (15)
- Women’s concerns about the emotional impact of awareness of heritable breast cancer risk and its implications for their children (2014) (15)
- Testing and counseling adults for heritable cancer risk. (1995) (15)
- A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease (2018) (15)
- Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
- Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. (2014) (15)
- The fuzzy world of precision medicine: deliberations of a precision medicine tumor board (2016) (15)
- Dysphagia, melanosis, gastrointestinal stromal tumors and a germinal mutation of the KIT gene in an Argentine family. (2014) (15)
- Histopathologic features of breast cancer in Li–Fraumeni syndrome (2020) (14)
- Germ-line msh 6 Mutations in Colorectal Cancer Families 1 (1999) (14)
- 331TiPOLYMPIA, NEO-OLYMPIA AND OLYMPIAD: RANDOMIZED PHASE III TRIALS OF OLAPARIB IN PATIENTS (PTS) WITH BREAST CANCER (BC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM). (2014) (14)
- Common Genetic Variants and Modification of Penetrance of BRCA 2-Associated Breast Cancer (2010) (14)
- Risk for breast cancer and management of unaffected individuals with non‐BRCA hereditary breast cancer (2020) (14)
- Genotype–phenotype associations among panel-based TP53+ subjects (2019) (13)
- Breast cancer risk reduction. (2010) (13)
- Distress and the parenting dynamic among BRCA1/2 tested mothers and their partners. (2014) (13)
- Prevalence of germline variants in inflammatory breast cancer (2019) (13)
- Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology. (2007) (12)
- Reassessing risk models for atypical hyperplasia: age may not matter (2017) (12)
- Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines (2020) (12)
- Pathologic Features and Immunophenotype of Estrogen Receptor–positive Breast Cancers in BRCA1 Mutation Carriers (2012) (12)
- Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing. (2019) (12)
- Reproducibility of Random Periareolar Fine Needle Aspiration in a Multi-Institutional Cancer and Leukemia Group B (CALGB) Cross-Sectional Study (2009) (11)
- Retinoblastoma protein expression and its predictors in triple-negative breast cancer (2020) (11)
- Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. (2012) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations. (2012) (11)
- Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing (2021) (11)
- A human breast atlas integrating single-cell proteomics and transcriptomics. (2022) (11)
- Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes (2018) (11)
- 216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) (2017) (11)
- Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side. (2009) (11)
- Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers. (2017) (10)
- The clinical and functional effects of TERT variants in myelodysplastic syndrome. (2021) (10)
- The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
- AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study (2007) (10)
- Towards Prevention of Breast Cancer: What Are the Clinical Challenges? (2018) (10)
- Time to Think Outside the (Genetic) Box (2011) (10)
- One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers. (2004) (10)
- The cancer predisposition revolution (2016) (10)
- Trans‐counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants (2019) (10)
- Ophira M. GinsburgCharmaine Kim-SingWilliam D. Foulkes • Parviz GhadirianHenry T. LynchPing SunSteven A. Narod • Hereditary Breast Cancer Clinical Study Group (2010) (9)
- Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
- The American society of clinical oncology position on genetic testing (1997) (9)
- Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
- Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. (2012) (9)
- Benefits and Risks of Screening Mammography in Women With BRCA1 and BRCA2 Mutations-Reply (1997) (9)
- Summarizing polygenic risks for complex diseases in a clinical whole-genome report (2014) (9)
- A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers (2020) (9)
- Genetic Testing for Susceptibility to Cancer (1998) (8)
- Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations (2021) (8)
- Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT). (2020) (8)
- Incidental breast carcinoma: incidence, management, and outcomes in 4804 bilateral reduction mammoplasties (2019) (8)
- Advances in Brief A Hereditary Nonpolyposis Colorectal Carcinoma Case Associated with Hypermethylation of the MLH 1 Gene in Normal Tissue and Loss of Heterozygosity of the Unmethylated Allele in the Resulting Microsatellite Instability-High Tumor 1 (2002) (8)
- Inherited breast cancer: increasingly familiar territory. (1998) (8)
- Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer (2021) (8)
- A Genomic-Profile Derived Summary Measure of Chromosomal Breakpoints Predicts Response to Treatment with the DNA-Damaging Agent Cisplatin. (2009) (8)
- Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. (2020) (8)
- Genetic/familial high-risk assessment (2010) (8)
- Trans-ethnic variation in germline variants of patients with renal cell carcinoma. (2021) (8)
- Modification of BRCA 1-and BRCA 2-associated Breast Cancer Risk by AIB 1 Genotype and Reproductive History 1 (2001) (7)
- A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer (2020) (7)
- Abstract POSTER-CTRL-1208: A dualistic model for the origin of high-grade serous carcinoma: BRCA mutation status, histology and tubal intraepithelial carcinoma (2015) (7)
- Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. (2022) (7)
- Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes (2011) (7)
- Diagnosis in Oncology. Leukemia cutis. (1997) (7)
- Breast Cancer Screening: A Final Analysis? (2003) (7)
- Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model (2021) (7)
- E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells (2020) (7)
- Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together. (2010) (7)
- BRCA1/2-Associated and Sporadic Breast Cancers: Fellow Travelers or Not? (2009) (6)
- Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D (2022) (6)
- OA 06.02 Final Report of the INHERIT EGFR Study - 33 Unrelated Kindreds Carrying Germline EGFR Mutations (2017) (6)
- Instability-High Tumor Unmethylated Allele in the Resulting Microsatellite Normal Tissue and Loss of Heterozygosity of the Gene in MLH 1 Associated with Hypermethylation of the A Hereditary Nonpolyposis Colorectal Carcinoma Case (2002) (6)
- "First do no harm" also applies to cancer susceptibility testing. (1996) (6)
- Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines (2022) (6)
- Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study (2021) (6)
- Surgical Complications and the Use of Neoadjuvant Bevacizumab. (2009) (6)
- Discussion: Hereditary Ovarian Cancer (2003) (6)
- Screening children at genetic risk of cancer. (1993) (6)
- PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
- Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer (2008) (6)
- Retinoblastoma (Rb) protein expression in triple-negative breast cancer. (2017) (6)
- Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk? (2019) (6)
- Follow-up of cancer family with in-vitro radioresistance (1990) (6)
- Genetic Variation in IGF 2 and HTRA 1 and Breast Cancer Risk among BRCA 1 and BRCA 2 Carriers (2011) (6)
- Family cancer history: healthy skepticism required. (2011) (6)
- Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics. (2016) (6)
- Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer (2020) (6)
- Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (5)
- Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case–Control Analysis Nested within the Nurses' Health Study II (2020) (5)
- Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. (2020) (5)
- Germ-line p 53 Mutations Predispose to a Wide Spectrum of Early-onset Cancers 1 (2001) (5)
- Case Report—Loyalty, Legacy, and Ledger: Contextual Therapy in a Patient with a Family History of Ovarian Cancer (1999) (5)
- The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial (2021) (5)
- Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial (2016) (5)
- Retinoblastoma protein expression and its predictors in triple-negative breast cancer (2020) (5)
- Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing (2021) (5)
- Sex Ratio Distortion in Offspring of Families with BRCA1 or BRCA2 Mutant Alleles: An Ascertainment Bias Phenomenon? (2005) (5)
- Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen (2022) (5)
- Germline BRCA 1 Mutations and Loss of the Wild-Type Allele in Tumors from Families with Early Onset Breast and Ovarian Cancer 1 (2005) (5)
- Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer (2015) (5)
- A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors. (2004) (5)
- Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen (2005) (5)
- CANCER GENETICS Gene for familial breast and ovarian cancer (1993) (5)
- Informing models of cancer genetics care in the era of multigene panel testing with patient‐led recommendations (2020) (5)
- Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
- Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs) (2021) (4)
- Novel Pathogenic Germline Variant of the Adenomatous Polyposis Coli (APC) Gene, p.S2627Gfs*12 Identified in a Mild Phenotype of APC-Associated Polyposis: A Case Report (2020) (4)
- Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits? (2020) (4)
- P4-11-13: Influence of Two Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer; a Companion Study to the NCIC CTG MAP.3 Trial. (2011) (4)
- Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial (2015) (4)
- Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition (2020) (4)
- Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. (2009) (4)
- Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. (2007) (4)
- Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk (2019) (4)
- Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model. (2019) (4)
- A randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). (2020) (4)
- Germline mutations in cancer predisposition genes among patients with thyroid cancer. (2017) (4)
- Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial (2020) (4)
- Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (4)
- The clinical and functional effects of TERT variants in myelodysplastic syndrome (2021) (4)
- Screening for Ovarian Cancer: What We Know, What We Need to Know (2000) (4)
- Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival. (2010) (4)
- Breast cancer phenotype in women with TP53 germ-line mutations: An LFS consortium effort. (2011) (4)
- Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects. (2019) (3)
- Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCAcarriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031) (2020) (3)
- Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer (2022) (3)
- A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome (2020) (3)
- Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. (2021) (3)
- Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics (2021) (3)
- Prevalence of ataxia-telangiectasia heterozygosity in patients developing contralateral breast cancer following treatment with conservative surgery and radiation therapy (1998) (3)
- Prospective Registry of Multiplex Testing (PROMPT): Feasible and sustainable. (2018) (3)
- Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. (2021) (3)
- Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. (2013) (3)
- Table 1. [Summary of Molecular Genetic Testing Used in Li-Fraumeni Syndrome]. (2013) (3)
- Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germlineBRCA1/2mutation (gBRCAm): (2015) (3)
- Breast MRI Wire-Guided Excisional Biopsy: Specimen Size as Compared to Mammogram Wire-Guided Excisional Biopsy and Implications for Use (2007) (3)
- Markers of risk for human malignancies. (1994) (3)
- Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2 (2022) (3)
- Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations (2019) (3)
- Quality or quantity in the management of hereditary ovarian cancer risk: Is it really a trade-off? (2005) (3)
- Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. A case report and brief literature review. (1988) (3)
- Prophylactic oophorectomies in women at high risk for ovarian cancer (1999) (3)
- Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. (2020) (3)
- Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis (2022) (3)
- Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. (2015) (3)
- Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer (2020) (3)
- Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. (2016) (3)
- Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis (2017) (2)
- Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. (2019) (2)
- Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC). (2015) (2)
- Predisposition Testing for Inherited Breast Cancer (1998) (2)
- Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma (2020) (2)
- Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition (2022) (2)
- Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi). (2021) (2)
- A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease. (2014) (2)
- Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment (2022) (2)
- Sensitivity of clinical BRCA1 testing compared with linkage analysis. (2012) (2)
- The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer (2010) (2)
- Investigating hereditary risk from T790M (inherit): A prospective multicentered study of risk associated with germ-line EGFR T790M. (2013) (2)
- P27 and pAKT Expression in BRCA1-associated and sporadic breast tumors. (2004) (2)
- Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis (2019) (2)
- Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial (2019) (2)
- Pathologic findings in reduction mammoplasty procedures identified by natural language processing of breast pathology reports: A surrogate for the population incidence of cancer and high risk lesions. (2018) (2)
- A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors (2004) (2)
- COMPELEMENTARY AND ALTERNATIVE MEDICINE USE AMANG WOMEN WITH BREAST CANCER (2002) (2)
- Hereditary ovarian cancer (2003) (2)
- S4-4: Clarifying the Risk of Breast Cancer in Women with Atypical Breast Lesions. (2011) (2)
- Parental decisions and outcomes regarding disclosing maternal BRCA1 and 2 test results to children. (2016) (2)
- Factors associated with genetic testing distress in patients tested for Lynch Syndrome or Hereditary Breast and Ovarian Cancer Syndrome (2011) (2)
- Vulvar Melanoma in association with germline MITF p.E318K variant. (2022) (2)
- Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data (2021) (2)
- Abstract OT3-01-04: VADIS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast (2017) (2)
- Reply to S.M. Sorscher and M.J. Hall et al. (2016) (2)
- REPORTS Multiple Primary Cancers in Families With Li-Fraumeni Syndrome (1998) (2)
- Perinephric abscess treated with sulphadiazine and penicillin. (1947) (2)
- DNA repair protein biomarkers in triple negative breast cancer. (2009) (2)
- Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study (2021) (2)
- Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes. (2021) (2)
- Histopathological features of breast cancers in women with germline TP53 mutations. (2006) (1)
- Abstract P1-08-07: Predisposing germline mutations in a clinic based breast cancer (BC) population (2016) (1)
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (1)
- Implications of genetic information at breast cancer diagnosis (2003) (1)
- Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants. (2016) (1)
- Gene for familial breast and ovarian cancer. (1993) (1)
- Fluvastatin has biologic effects on stage 0 and 1 breast cancer. (2009) (1)
- Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program (2021) (1)
- Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (1)
- Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition (2022) (1)
- Nearly half of TP53 variants are misattributed to Li-Fraumeni syndrome: A clinical evaluation of individuals with TP53 variants detected by hereditary cancer panel assays on blood or saliva. (2021) (1)
- Syddansk Universitet Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12 p 11 locus (2016) (1)
- Genetic counseling processes and outcomes among prostate cancer patients (ProGen). (2019) (1)
- Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers (2011) (1)
- A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer. (2010) (1)
- Prospective Registry of Multiplex Testing (PROMPT): Follow-up. (2019) (1)
- NCCN Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology (2010) (1)
- phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers (2015) (1)
- Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study (2016) (1)
- Abstract 2417: The INHERIT EGFR study: Investigating hereditary risk from T790M. (2013) (1)
- Cancer patients' preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. (2014) (1)
- Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: The GENetic Education, Risk Assessment and TEsting (GENERATE) study. (2019) (1)
- Genetic testing for susceptibility to cancer. Task Force on Cancer Genetics Education. (1998) (1)
- Familial cancer database online. (2008) (1)
- Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2 (2008) (1)
- Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
- A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer. (2010) (1)
- Abstract 3376: Reprogramming the estrogen signaling network is a potential mechanism for human breast tumorigenesis (2017) (1)
- Results of a randomized controlled trial of a decision support intervention for disclosing maternal BRCA genetic test results to children and adolescents (2023) (1)
- Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
- Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply. (2021) (1)
- Assessing patient satisfaction in a BRCA1/2 testing program (1999) (1)
- Deliberations of a precision medicine tumor board. (2016) (1)
- An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: Using somatic genome to inform the role of germline variants (2022) (1)
- Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. (2021) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study. (2015) (1)
- Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception. (2023) (1)
- The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (1)
- Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
- Impact of genetic testing on risk-reducing behavior in women at risk for hereditary gynecologic cancer syndromes (2010) (1)
- Abstract OT2-09-01: Pilot study of denosumab inBRCA1/2mutation carriers scheduling for risk-reducing salpingo-oophorectomy (2019) (1)
- 7N Local therapy options in BRCA1/2 carriers with operable breast cancer: the importance of adjuvant chemotherapy (2010) (1)
- Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study (2019) (1)
- The BRCA founder outreach study: Initial results of a digital health model. (2020) (1)
- 5 Family history suggestive of an inherited susceptibility to breast cancer and treatment outcome in young women after breast-conserving therapy (1997) (1)
- Characterization of estrogen receptor-positive breast cancers inBRCA1mutation carriers. (2009) (1)
- Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC) (2013) (1)
- Developing infrastructure to improve research and care for cancer survivors: A pilot study. (2016) (1)
- Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers (2015) (1)
- Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): Results of CALGB (Alliance) 70806. (2018) (1)
- P1-09-03: Prevalence of Germline TP53 Mutations in Young Women with HER2−Positive Breast Cancer. (2011) (1)
- S6 Breast cancer genetics: clues to tumor biology (2007) (1)
- One step forward, two steps backward (2019) (1)
- Screening with whole-body MRI (WB-MRI) in pediatric patients with Li Fraumeni syndrome (LFS). (2013) (1)
- S2 Genetic counseling: Therapeutic consequences (2005) (1)
- Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. (2013) (1)
- THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. (2016) (1)
- S6-1: Menopause-Specific and Health-Related Qualities of Life among Post-Menopausal Women Taking Exemestane for Prevention of Breast Cancer: Results from the NCIC CTG MAP.3 Placebo-Controlled Randomized Controlled Trial. (2011) (1)
- Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells. (2012) (1)
- Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. (2022) (0)
- BRCA1 c.5181_5183delGTT (p.Val1688del) is a true pathogenic mutation that affects both protein stability and function: implications for genetic counseling. (2009) (0)
- Abstract 1120: Randomized clinical trial of a flaxseed lignan in pre-menopausal women at high risk for development of breast cancer (2020) (0)
- Genetic testing experiences and emotional reactions among individuals with variant of uncertain significance results from cancer multiplex genetic testing. (2020) (0)
- Germline TP53 mutations in women with very early onset breast cancer (BR) (2005) (0)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
- A pilot intervention addressing sexual dysfunction after risk-reducing oophorectomy. (2013) (0)
- Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. (2016) (0)
- Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutations (2021) (0)
- Abstract 989: Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages and can form chimeric mammary glands in vivo (2018) (0)
- Communication of BRCA1/2 test results to first-degree relatives (FDRs): Factors predicting who women tell. (2004) (0)
- OP013: Landscape of germline pathogenic variants in cancer susceptibility genes in patients with sarcoma (2022) (0)
- Commentary on “Prophylactic Surgery for Women at High Risk for Breast Cancer” (2000) (0)
- Features of familiality in a cohort of patients (pts) with sarcoma. (2012) (0)
- Prevalence of hereditary GIST susceptibility in adults with GIST. (2011) (0)
- Women’s concerns about the emotional impact of awareness of heritable breast cancer risk and its implications for their children (2014) (0)
- Estrogen Rececptor (ER)-Positive Breast Cancers inBRCA1Mutation Carriers: Mutation-Related or Sporadic?: (2009) (0)
- Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model. (2020) (0)
- Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers (2023) (0)
- Abstract LB-257: Estrogen signaling in mature luminal and luminal progenitor cells of BRCA2 carriers and non-carriers (2017) (0)
- Genome-wide analysis and characterization of an online sarcoma cohort. (2012) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Ethnicity-Specific Variation in the Germline Landscape of Renal Cell Carcinoma (2020) (0)
- P3-11-04: A Randomized Phase II Biomarker Study of Atorvastatin in Premenopausal Women at Increased Risk for Breast Cancer. (2011) (0)
- Cancer surveillance is often inadequate in individuals at high risk for colorectal cancer (CRC) (2000) (0)
- Abstract A15: Immune-related changes in breast cancer tumor evolution (2018) (0)
- Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages (2020) (0)
- Comparison of complementary medicine use at genetic testing program enrollment and one-year following results disclosure. (2004) (0)
- Abstract LB-162: BRCA2, and not BRCA1, dependent crosstalk between replication stress suppression and nucleotide excision repair - Clinical implications (2016) (0)
- Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer. (2017) (0)
- Shared heritability and functional enrichment across six solid cancers (2019) (0)
- Commentary (Garber): Advising Women at High Risk of Breast Cancer (2004) (0)
- 492 High Prevalence of Gastric Cancer in Families with Germline TP53 Mutations (2008) (0)
- Clinical conundrums: Developing a strategy for discerning TP53-associated chip and coherent clinical care. (2020) (0)
- Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. (2016) (0)
- Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases. (2013) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Clonal hematopoiesis and mosaicism revealed by a multi-tissue analysis of constitutional TP53 Status. (2022) (0)
- Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2. (2017) (0)
- Estradiol and breast cancer risk. (2006) (0)
- Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer (2022) (0)
- University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
- IN6 Cancer risk-reducing measures for high risk women (2012) (0)
- Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma (2019) (0)
- Abstract P4-12-03: Triple-negative breast cancer: Frequency of inherited mutations in breast cancer susceptibility genes (2015) (0)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
- Commentary on Eccles et al.: Familial breast cancer: an investigation into the outcome of treatment for early stage disease (2004) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract S5-05: Defective stalled replication fork repair and predisposition to hereditary breast cancer (2015) (0)
- Reply to S. Takamizawa et al. (2020) (0)
- A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study). (2022) (0)
- Breast Cancer Genetics (2017) (0)
- Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | NOVA. The University of Newcastle's Digital Repository (2014) (0)
- Abstract P2-09-03: Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden (2022) (0)
- Abstract A20: Random periareolar fine‐needle aspiration is highly reproducible in a CALGB multi‐institutional cross‐sectional study (2010) (0)
- BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: Patterns, motivations, and implications for treatment decisions. (2014) (0)
- Low-dose Tamoxifen For Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial (2019) (0)
- ‘Case of the Month’ from Brigham and Women’s Hospital, Boston, MA, USA: a 70‐year‐old man with lung cysts and bilateral renal masses (2020) (0)
- Factors affecting surgical decision-making in patients undergoingBRCA1/2testing at breast cancer diagnosis. (2009) (0)
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
- Factor V l eiden Mutation and t hromboembolism r isk in Women r eceiving Adjuvant t amoxifen for Breast c ancer (2010) (0)
- Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers (2022) (0)
- Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study (2017) (0)
- Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib (2023) (0)
- PG 6.01 Using germline genetics in the management of breast cancer patients and their families (2015) (0)
- PO18 BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: patterns; motivations and implications for treatment decisions (2014) (0)
- ASO Visual Abstract: Screening MRI Does Not Increase Cancer Detection or Result in Earlier Stage at Diagnosis in Patients with High-Risk Breast Lesions–A Propensity Score Analysis (2022) (0)
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
- Anticipated V ersus A ctual E motional R eactions t o Disclosure o f R esults o f G enetic T ests f or Cancer S usceptibility: F indings F rom p53 and BRCA1 Testing P rograms (2000) (0)
- Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration. (2016) (0)
- Male breast cancer in BRCA1 and BRCA2 mutation carriers (2018) (0)
- A randomized trial of two different genetic counseling interventions for BRCA1/2 genetic testing. (2004) (0)
- A counseling framework for moderate-penetrance colorectal cancer susceptibility genes (2018) (0)
- Imaging , Diagnosis , Prognosis DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer (2010) (0)
- Genetic susceptibility for breast cancer[mdash ]Risk assessment and counseling (2001) (0)
- Radiation-Related Toxicities in Patients with Known Pathogenic Mutations in Cancer Susceptibility Genes Treated Definitively for Breast Cancer (2019) (0)
- Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ (2023) (0)
- Breast Cancer Risk Reduction , Version 2 . 2015 Clinical Practice Guidelines in Oncology (2015) (0)
- Abstract PD01-08: Differences in estrogen receptor signaling in non-malignant primary ER-positive breast epithelial cells and breast cancer. (2012) (0)
- Price Forex Elgg. Transfer the Content of Each Well Mto a Scintillation Vial. Conceptual Approaches to Price Forex Elgg >>>>click Here<<<< Price Forex Elgg (2015) (0)
- Abstract LB-245: Validating models of imputing germline versus somatic status for variants detected by tumor-only genomic profiling using germline clinical testing data (2020) (0)
- Abstract P5-03-16: Changes in preferences for ovarian cancer prevention strategies during the COVID-19 pandemic: Results of a discrete choice experiment (2023) (0)
- Li-Fraumeni Exploration Consortium Data Coordinating Center: A web-based resource for collaborative epidemiologic research on a rare cancer syndrome. (2020) (0)
- Table 2. [Tumor-Specific Cancer Risks in Families with LFS Who Have Germline TP53 Pathogenic Variants]. (2013) (0)
- Colorectal cancer knowledge and screening rates are lower than for breast cancer even in individuals at high risk of cancer (2001) (0)
- Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the anti-tumor potential of TAMs (2020) (0)
- Title: Evolutionary pathways in BRCA1-associated breast tumors (2012) (0)
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
- Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (0)
- Abstract 2406: A general probabilistic algorithm to predict de novo mutations in familial diseases as demonstrated in Li-Fraumeni Syndrome (2019) (0)
- Abstract OT3-09-02: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ (DCIS) (2020) (0)
- Volume Contents (2004) (0)
- Treatment selection for patients with BRCA mutation (2019) (0)
- PARP inhibition in breast cancer. (2009) (0)
- Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx). (2015) (0)
- Development and validation of the PREMMplus clinical prediction model for multigene hereditary cancer risk assessment. (2020) (0)
- An integrated somatic and germline approach to aid interpretation of germline variants of uncertain significance in cancer susceptibility genes (2022) (0)
- Effect of hierarchical clustered sampling in multicenter, family-based studies: Example of reproductive history and breast cancer risk in BRCA1 mutation carriers. (2000) (0)
- Genetic testing in patients with triple negative or hereditary breast Cancer (2021) (0)
- S4 Genetics in cancer prevention (2010) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- PARP inhibition in breast cancer: progress made and future hopes (2022) (0)
- A Randomized Study of the Effects of Tibolone on Bone Density, Menopausal Symptoms, and Breast Density in High-Risk Women After Prophylactic Oophorectomy (2004) (0)
- Abstract P5-14-03: Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study (2023) (0)
- S11 Implications of inherited predisposition for surveillance, risk reduction and treatment (2009) (0)
- Abstract OT3-3-01: A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors (2013) (0)
- Occult O varian T umors i n W omen W ith BRCA1 or BRCA2 Mutations U ndergoing P rophylactic O ophorectomy (2000) (0)
- Abstract PD1-02: Statin use and breast cancer incidence in the Nurses' health study (2016) (0)
- The risks and benefits of panel germline testing in breast cancer (BC) (2017) (0)
- BRCA I Maps Proximal to D I 7S579 on Chromosome 1 7q2 I by Genetic Analysis (2006) (0)
- Iconographies supplémentaires de l'article : The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy (2011) (0)
- Pediatric BRCA1/2 Testing Attitudes Scale (2015) (0)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
- Rate of incidental germline findings detected by tumor-normal matched sequencing in cancer types lacking hereditary cancer testing guidelines. (2021) (0)
- Abstract 4823: Copy number gain and increased expression of BLM and FANCI is associated with sensitivity to genotoxic chemotherapy in triple negative breast and serous ovarian cancer (2012) (0)
- Abstract PD10-09: Development of a breast cancer risk assessment model forATMmutation carriers incorporating tyrer-cuzick and a polygenic risk score (PRS) (2021) (0)
- Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations (2020) (0)
- Cancer Genomics in the Clinic: Methods and Lessons (2013) (0)
- Abstract PD14-09: PD14-09 The effect of timing of TP53 genetic testing on treatment and outcomes among women with Li-Fraumeni syndrome and breast cancer (2023) (0)
- Book Review Oral Contraceptives and Breast Cancer By a committee of the Institute of Medicine. 185 pp. Washington, D.C., National Academy Press, 1991. $24.95. (1992) (0)
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (2016) (0)
- Abstract PO-013: Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) study (2021) (0)
- Impact of Genetic Counseling on Patient-Reported Electronic Cancer Family History Collection. (2022) (0)
- Examining patients’ medical and psychosocial experiences following detection of a CDH1 variant with multiplex genetic testing. (2018) (0)
- Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers? (2018) (0)
- Impact of mismatch repair (MMR) genetic test result on perceived cancer risk and cancer screening (2010) (0)
- Abstract P4-03-02: Casting a wide net: Finding actionable results in non-breast cancer (BC) genes on multi-gene panel testing (MGPT) in a BC cohort (2019) (0)
- Genetic testing in young women with breast cancer: Results from a web-based survey (2007) (0)
- University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch, (2013) (0)
- Abstract 6084: The Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network directly engage patient participants in genomics research (2023) (0)
- Determination of factors predicting for estrogen receptor positive (ER+) breast cancers in BRCA1 mutation carriers. (2016) (0)
- Abstract A029: A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer (2022) (0)
- 163 Contralateral breast cancer after conservative surgery and radiation therapy in early-stage breast cancer (1999) (0)
- Abstract P6-02-08: Identifying preferences that may motivate choice of ovarian cancer risk prevention strategies using a discrete choice experiment (2023) (0)
- Breast Cancer Screening and DiagnosisPractice Guidelines in Oncology TM (2009) (0)
- Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (0)
- Abstract P3-04-03: The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study (2022) (0)
- Aromatase Inhibitors as Chemopreventives of Breast Cancer (2004) (0)
- Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer (2022) (0)
- Prevalence of pathogenic germline risk variants (PVs) in 1,829 renal cell carcinoma (RCC) patients (pts). (2020) (0)
- Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer (2018) (0)
- Proteomic Analyses of Nipple Fluid for Early Detection of Breast Cancer (2008) (0)
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (0)
- Abstract PR05: Distinct BRCA1- and BRCA2-specific functions at stalled replication forks: Clinical implications for differences between BRCA1 and BRCA2 mutation-driven cancer (2017) (0)
- Abstract ES2-3: Managing increased breast cancer risk based on high and moderate penetrance gene mutations (2018) (0)
- Abstract OT-20-01: Genetic testing for all breast cancer patients (get facts) (2021) (0)
- Abstract PD3-07: A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ (2019) (0)
- Abstract P5-06-04: Distinct BRCA1 and BRCA2 specific functions at stalled replication forks - Clinical implications for differences between BRCA1 and BRCA2 mutation driven cancer (2017) (0)
- Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT). (2016) (0)
- Incidental atypical hyperplasia/LCIS in mammoplasty specimens and subsequent risk of breast cancer. (2019) (0)
- Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (2017) (0)
- 860 Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer (2020) (0)
- Abstract P5-04-06: Breast Imaging Recommendations for Females <40 Years of Age with ≥20% Lifetime Breast Cancer Risk: Practice Patterns at a Specialized Clinic (2023) (0)
- Abstract OT3-15-02: A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts (2020) (0)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
- The value of studying cancer families. (1990) (0)
- Questioning a Li-Fraumeni Syndrome diagnosis: Characterization of a commonly observed germline TP53 variant, p.Arg156His. (2022) (0)
- Abstract P5-12-03: Withdrawn (2018) (0)
- Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. (2022) (0)
- Abstract A21: Characterization of the immune environment in the in situ to invasive breast carcinoma transition (2018) (0)
- S15. Cancer prevention and genetic testing: An update (2008) (0)
- Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes (2017) (0)
- Table 1. [Molecular Genetic Testing Used in Li-Fraumeni Syndrome]. (2019) (0)
- Distant recurrences in triple negative breast cancer (TNBC) according to androgen receptor (AR) status. (2016) (0)
- Abstract PD7-03: A living biobank of normal mammary organoids derived from patients at low and increased risk of developing breast cancer (2021) (0)
- Genotype–phenotype associations among panel-based TP53+ subjects (2019) (0)
- THE ASSOCIATION OF LOBULAR BREAST CANCER WITH GERMLINE MUTATIONS OF CDH1 (2008) (0)
- Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers. (2021) (0)
- Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model (2022) (0)
- Genetic risk assessment and beyond: Anything new? (2006) (0)
- Commentary (Masciari/Garber): Evaluation and Management of Women With BRCA1/2 Mutations (2005) (0)
- Abstract A105: PARP inhibition modulates the infiltration, phenotype, and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the antitumor potential of TAMs (2020) (0)
- CANCER GENETICS 1. NEW CHALLENGES IN TREATMENT FOCUSED GENETIC TESTING: A GENETIC COUNSELING PERSPECTIVE (2017) (0)
- A randomized study of cash cards versus checks as clinician survey incentives (2020) (0)
- Abstract P017: Early detection of ovarian cancer in high-risk individuals using circulating miRNAs: The MiDe study (2023) (0)
- Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer (2021) (0)
- P-060: Pathogenic germline mutations in a large cohort of multiple myeloma (2022) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings (2017) (0)
- BRCA1/2 testing: therapeutic implications for breast cancer management (2018) (0)
- NCCN Genetic/Familial High-Risk Assessment: Breast Panel Members Genetic/Familial High-Risk Assessment: Breast (2002) (0)
This paper list is powered by the following services:
Other Resources About Judy E. Garber
What Schools Are Affiliated With Judy E. Garber?
Judy E. Garber is affiliated with the following schools:
- University of Cambridge
- Harvard University
- Medical University of Vienna
- Institute of Cancer Research
- Icahn School of Medicine at Mount Sinai
- Baylor College of Medicine
- University of Toronto
- Massachusetts General Hospital
- Technical University of Denmark
- McGill University
- Ohio State University
- University of British Columbia
- Georgetown University
- Queen Mary University of London
